Moderna shares soar on melanoma drug trial success

Vaccine stocks have experienced a significant jump following the announcement of successful trial results for Moderna's melanoma vaccine. Shares of Moderna soared as the market reacted positively to the drug trial's success. This development has driven a broader increase in the valuation of companies within the vaccine sector, reflecting investor confidence in the efficacy of the new melanoma treatment developed by Moderna as reported across multiple financial news sources.